BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Ascletis’ ASC47 Plus Tirzepatide Shows 87% Greater Weight Loss Than Tirzepatide Alone in Preclinical Obesity Study

The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to t...

August 13, 2025 | News

RemeGen Secures FDA Clearance for Phase II Trials of Innovative Bispecific Antibody RC148 in Advanced Solid Tumors

RemeGen Co., announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bisp...

August 11, 2025 | News

Senhwa Advances CX-5461 into NCI-Sponsored Trial for MYC-Aberrant Lymphoma

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

August 08, 2025 | News

PolyActiva Launches U.S. Trial of Glaucoma Implant Following Australia Success

PA5108, a new chemical entity, is an investigational, biodegradable ocular micro implant, designed to deliver sustained intraocular pressure control for ...

August 08, 2025 | News

Fapon Biopharma Enrolls First Patient in China Phase I Trial of Novel Immunotherapy FP008 for Solid Tumors

Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollmen...

August 06, 2025 | News

iNtRON Bio Unveils World-First Dual-Action Engineered Phage Targeting Colorectal Cancer-Causing Bacteria

Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeut...

August 06, 2025 | News

Innovent Biologics gets FDA nod to begin Phase 1 trials of oral GLP-1R agonist IBI3032

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

August 05, 2025 | News

WuXi XDC’s New DP3 Facility Achieves GMP Release, Boosting Global Bioconjugate Manufacturing Capacity

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...

August 05, 2025 | News

Bridging Real-World Evidence and AI: Unlocking Smarter, Faster Clinical Research in Asia

Having worked with pharma clients, healthcare providers, and digital platforms across the Asia-Pacific region, I’ve seen the challenges first-hand&md...

August 04, 2025 | Opinion

Chipscreen Biosciences Receives FDA IND Approval for Brain-Penetrant Aurora B Inhibitor CS231295

Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has rec...

August 04, 2025 | News

Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma

Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory C...

August 04, 2025 | News

Energenesis Completes Phase I Trial of ENERGI-F705PD, a Novel Oral Therapy for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pha...

August 04, 2025 | News

Luye Pharma Begins Phase 1 Trial of Novel Triple-Target Antidepressant LY03021 in China

Luye Pharma Group announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed ...

August 04, 2025 | News

Alphamab Oncology’s Bispecific ADC JSKN022 Clears IND Review in China

Alphamab Oncology announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug...

August 04, 2025 | News

Stay Connected